

Primary aldosteronism screen cost-effective in resistant HTN

16 November 2015



ratios were \$200,000/QALY and \$492,000/QALY, respectively; other strategies were less effective and more costly.

"Primary hyperaldosteronism is a common disease that is currently, grossly underdiagnosed and treated," the authors write. "Our results suggest that CT followed by AVS is a cost-effective strategy to screen for PA among [patients](#) with RH."

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

(HealthDay)—For patients with resistant hypertension (RH), computed tomography (CT) scanning followed by adrenal venous sampling (AVS) is a cost-effective screen for primary aldosteronism (PA), according to a study published online Nov. 10 in *Circulation: Cardiovascular Quality and Outcomes*.

Copyright © 2015 [HealthDay](#). All rights reserved.

Carrie C. Lubitz, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues examined whether the long-term cardiovascular benefit of identifying and treating surgically correctable PA outweighs the increased [upfront costs](#). A decision-analytic model was used to compare aggregate costs and [systolic blood pressure](#) changes for six diagnostic strategies for PA in a simulated population of at-risk RH patients. A seventh strategy whereby all patients were treated with a mineralocorticoid-receptor antagonist without further testing was also evaluated. Changes in systolic blood pressure were converted into gains in quality-adjusted life-years (QALYs); incremental cost-effectiveness ratios were calculated using QALYs and lifetime costs.

The researchers found that, compared with treating all, the incremental cost-effectiveness ratio for CT followed by AVS was \$82,000/QALY. For CT alone and AVS alone, the incremental cost-effectiveness

APA citation: Primary aldosteronism screen cost-effective in resistant HTN (2015, November 16) retrieved 16 September 2022 from <https://medicalxpress.com/news/2015-11-primary-aldosteronism-screen-cost-effective-resistant.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.